Regeneron Pharmaceuticals
About
Regeneron Pharmaceuticals (NASDAQ: REGN) is a leading biotechnology company known for its innovative drug discovery platform and blockbuster portfolio anchored by Eylea for retinal diseases, Dupixent for inflammatory conditions, and Libtayo for certain cancers, with Dupixent alone generating over $10 billion in annual global sales. The company's proprietary VelociSuite technology platform enables rapid and efficient drug development, consistently producing a pipeline that ranks among the most productive in the industry. As an investment, Regeneron combines strong current earnings with significant growth potential from label expansions of existing drugs and a deep pipeline of novel antibody-based therapies across immunology, oncology, and genetic medicine.
Biotech Stocks
Regeneron is a top-tier biotech stock powered by its industry-leading antibody discovery platform and the explosive growth of Dupixent across multiple inflammatory indications, demonstrating the kind of science-driven innovation and commercial execution that biotech investors seek.
Key Financials REGN
Price
$803.17
Change (1D)
+2.49%
Change (30D)
+4.06%
Change (60D)
+14.04%
Change (90D)
+37.18%
Change (180D)
+35.70%
Change (1Y)
+20.98%
Change (5Y)
+63.69%
P/E Ratio
32.77
EPS (TTM)
$24.51
52-Week Range
$476.49 — $821.11
50-Day MA
$759.85
Volume
974.7K
Data updated Feb 15 · Source: Twelve Data
